Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of the Vascular Disrupting Agent NPI-2358 in Combination With Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer

Next Previous
Search
Trial Profile

Study of the Vascular Disrupting Agent NPI-2358 in Combination With Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plinabulin (Primary) ; Docetaxel
  • Indications Neutropenia; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ADVANCE
  • Sponsors Nereus Pharmaceuticals

    • Most Recent Events

    • 06 Jun 2023 Results of post-hoc analysis assessing safety, tolerability, and QoL in NSCLC patients from these trials, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2023 Pooled analysis of NCT02504489; NCT03102606; NCT00630110 trials presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 13 Dec 2022 Results from two clinical studies: Phase 2 Study 101 (NCT00630110) and Phase 3 Study 103 (NCT02504489), assessing effectiveness of Plinabulin versus control for prevention of Docetaxel Docetaxel induced neutropenia (DIN) in NSCLC presented at the 64th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top